trandolapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 2712 87679-37-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trandolapril
  • gopten
  • mavik
  • odrik
The effect of trandolapril in hypertension appears to result primarily from the inhibition of circulating and tissue ACE activity thereby reducing angiotensin II formation, decreasing vasoconstriction, decreasing aldosterone secretion, and increasing plasma renin. Decreased aldosterone secretion leads to diuresis, natriuresis, and a small increase of serum potassium. Trandolapril is deesterified to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE activity.
  • Molecular weight: 430.55
  • Formula: C24H34N2O5
  • CLOGP: 2.10
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -4.32
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.06 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 10 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.25 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.17 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.26 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.495 High 0.96
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.811 High 0.96
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 10.691 10^-6 cm/s High 0.96
dh-clint Dog hepatocyte intrinsic clearance 16.749 uL/min/10^6 cells High 0.96
dppb Dog plasma protein binding (% unbound) 7.420 % High 0.96
fcs-ppb Fetal calf serum protein binding (% unbound) 8.030 % High 0.96
herg hERG pIC50 4.313 pIC50 High 0.96
hh-clint Human hepatocyte intrinsic clearance 20.045 uL/min/10^6 cells High 0.96
hlm-clint Human liver microsomal intrinsic clearance 24.491 uL/min/mg protein High 0.96
hppb Human plasma protein binding (% unbound) 8.610 % High 0.96
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1 24
kinase-selectivity-class AXL,BRAF,GRK2,MAP2K6 4
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 5.309 Moderate 0.68
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.089 High 0.96
mh-clint Mouse hepatocyte intrinsic clearance 72.277 High 0.96
mppb Mouse plasma protein binding (% unbound) 6.600 High 0.96
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 11.776 High 0.96
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 9.960 % High 0.96
rat-kpuu-brain Rat brain Kpuu 0.009 % Moderate 0.68
rh-clint Rat hepatocyte intrinsic clearance 101.859 uL/min/10^6 cells High 0.96
rh-fuinc Rat hepatocyte fraction unbound in incubation 78.750 % High 0.96
rppb Rat plasma protein binding (% unbound) 7.660 % High 0.96
solubility-dd Solubility at pH 7.4 in DMSO 1009.253 uM High 0.96

Approvals:

DateAgencyCompanyOrphan
April 26, 1996 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paranoia 70.59 20.46 25 3909 12883 90611630
Lactic acidosis 69.94 20.46 37 3897 50426 90574087
Hallucination, auditory 58.29 20.46 23 3911 15952 90608561
Psychotic disorder 55.21 20.46 27 3907 31203 90593310
Focal segmental glomerulosclerosis 48.17 20.46 12 3922 1839 90622674
Cerebellar haematoma 41.09 20.46 8 3926 392 90624121
Endometrial ablation 38.81 20.46 9 3925 1020 90623493
Red blood cells urine positive 37.16 20.46 11 3923 3214 90621299
Hyperaesthesia 34.17 20.46 14 3920 10688 90613825
Bacterial test 32.79 20.46 8 3926 1125 90623388
White blood cells urine positive 29.60 20.46 11 3923 6487 90618026
Acute kidney injury 29.35 20.46 51 3883 320336 90304177
Dyspnoea 29.19 20.46 94 3840 880861 89743652
Ventricular hypokinesia 27.89 20.46 10 3924 5331 90619182
Urine abnormality 27.73 20.46 11 3923 7726 90616787
Cardiac failure chronic 27.35 20.46 10 3924 5636 90618877
Orthopnoea 25.49 20.46 10 3924 6825 90617688
Cough 25.42 20.46 52 3882 368910 90255603
Pneumonia 24.73 20.46 72 3862 637987 89986526
Asthma 24.08 20.46 40 3894 242120 90382393
Oxygen saturation decreased 23.39 20.46 26 3908 107457 90517056
Exposure to SARS-CoV-2 22.42 20.46 7 3927 2445 90622068
Dorsal ramus syndrome 21.77 20.46 4 3930 143 90624370
Congestive cardiomyopathy 21.38 20.46 9 3925 7345 90617168
Organising pneumonia 21.10 20.46 9 3925 7588 90616925
Cardiogenic shock 20.64 20.46 13 3921 24455 90600058
Pharyngeal paraesthesia 20.64 20.46 7 3927 3167 90621346

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oesophageal obstruction 73.44 18.69 16 4240 586 42616493
Bezoar 61.48 18.69 16 4240 1260 42615819
Hypertensive encephalopathy 54.29 18.69 12 4244 470 42616609
Substance use 51.98 18.69 15 4241 1736 42615343
Arterial disorder 38.05 18.69 11 4245 1281 42615798
Oesophageal haemorrhage 28.54 18.69 9 4247 1405 42615674
Cough 27.36 18.69 57 4199 178046 42439033
Reading disorder 27.01 18.69 7 4249 542 42616537
Lid sulcus deepened 25.66 18.69 5 4251 104 42616975
Jugular vein distension 25.48 18.69 7 4249 677 42616402
Colectomy total 24.78 18.69 6 4250 352 42616727
Wrong product administered 24.16 18.69 12 4244 6214 42610865
Lactic acidosis 24.07 18.69 26 4230 45235 42571844
Eosinophil count increased 23.03 18.69 14 4242 10749 42606330
Waist circumference increased 22.97 18.69 7 4249 977 42616102
Body mass index increased 21.48 18.69 7 4249 1214 42615865
Hypotension 21.16 18.69 65 4191 257566 42359513
Bronchial wall thickening 20.74 18.69 7 4249 1353 42615726
Suspected COVID-19 20.39 18.69 7 4249 1423 42615656
Libido decreased 20.30 18.69 10 4246 5088 42611991
Dysgraphia 19.91 18.69 8 4248 2520 42614559
Drug interaction 18.87 18.69 64 4192 266935 42350144

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 89.06 17.08 63 7381 92748 110489107
Oesophageal obstruction 68.16 17.08 16 7428 1227 110580628
Psychotic disorder 66.76 17.08 42 7402 50895 110530960
Cough 51.86 17.08 103 7341 461538 110120317
Bezoar 49.43 17.08 16 7428 4038 110577817
Substance use 48.05 17.08 14 7430 2492 110579363
Paranoia 46.78 17.08 25 7419 22349 110559506
Acute kidney injury 39.89 17.08 113 7331 635317 109946538
Reading disorder 38.23 17.08 10 7434 1195 110580660
Hallucination, auditory 37.70 17.08 23 7421 26374 110555481
Arterial disorder 36.45 17.08 11 7433 2208 110579647
Endometrial ablation 35.61 17.08 9 7435 939 110580916
Hyperkalaemia 34.37 17.08 44 7400 135752 110446103
Cerebellar haematoma 33.92 17.08 8 7436 626 110581229
Oesophageal haemorrhage 29.40 17.08 9 7435 1894 110579961
Bacterial test 28.92 17.08 8 7436 1181 110580674
Hypotension 28.86 17.08 89 7355 523760 110058095
Red blood cells urine positive 27.31 17.08 11 7433 5174 110576681
Hypoglycaemia 25.34 17.08 35 7409 116069 110465786
Colectomy total 25.09 17.08 6 7438 498 110581357
Dysgraphia 24.85 17.08 10 7434 4695 110577160
Lid sulcus deepened 24.31 17.08 5 7439 207 110581648
White blood cells urine positive 23.37 17.08 11 7433 7513 110574342
Libido decreased 22.61 17.08 10 7434 5925 110575930
Jugular vein distension 22.26 17.08 7 7437 1609 110580246
Waist circumference increased 21.52 17.08 7 7437 1794 110580061
Hyperaesthesia 21.46 17.08 13 7431 14714 110567141
Urine abnormality 21.39 17.08 11 7433 9085 110572770
Drug interaction 20.49 17.08 77 7367 500106 110081749
Cardiogenic shock 20.17 17.08 22 7422 57316 110524539
Oxygen saturation decreased 19.98 17.08 37 7407 156945 110424910
Hypertensive encephalopathy 19.88 17.08 6 7438 1205 110580650
Body mass index increased 19.75 17.08 7 7437 2323 110579532
Eosinophil count increased 19.49 17.08 14 7430 21044 110560811
Focal segmental glomerulosclerosis 19.13 17.08 8 7436 4137 110577718
Dizziness 19.01 17.08 95 7349 698098 109883757
Spinal pain 18.74 17.08 13 7431 18502 110563353
Coagulopathy 18.56 17.08 18 7426 40893 110540962
Blood pressure decreased 18.40 17.08 30 7414 115061 110466794
Exposure to SARS-CoV-2 18.21 17.08 7 7437 2912 110578943
Dyspnoea 17.65 17.08 131 7313 1106741 109475114
Bronchial wall thickening 17.57 17.08 7 7437 3200 110578655
Itching scar 17.15 17.08 3 7441 51 110581804
Cardiac failure chronic 17.12 17.08 11 7433 13800 110568055

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BB10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:49103 drug metabolite
CHEBI has role CHEBI:76967 human xenobiotic metabolite

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs
benazeprilcaptoprilcilazaprildelaprilenalaprilfosinoprilimidaprillisinoprilmoexiprilperindoprilquinaprilramipril show all 15 →
C09BB ACE inhibitors and calcium channel blockers 13 drugs
amlodipinebenazeprildelaprilenalaprilfelodipinelercanidipinelisinoprilmanidipinenitrendipineperindoprilramiprilverapamil show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Left ventricular cardiac dysfunction indication 429589006
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Hyperkalemia contraindication 14140009
Ventricular tachycardia contraindication 25569003
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Sick sinus syndrome contraindication 36083008 DOID:13884
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Low cardiac output syndrome contraindication 44088000
Low blood pressure contraindication 45007003
Bradycardia contraindication 48867003
Lown-Ganong-Levine syndrome contraindication 55475008 DOID:13087
Aortic valve stenosis contraindication 60573004 DOID:1712
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Transplantation contraindication 77465005
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Second degree atrioventricular block contraindication 195042002
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Neuromuscular Transmission Deficiency contraindication
Hemodialysis with High-Flux Membrane contraindication
First Degree Atrioventricular Heart Block contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.23 acidic
pKa2 5.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 8.12 WOMBAT-PK CHEMBL

External reference:

IDSource
4020971 VUID
N0000148444 NUI
D00383 KEGG_DRUG
4020971 VANDF
C0076891 UMLSCUI
CHEBI:9649 CHEBI
X93 PDB_CHEM_ID
CHEMBL1519 ChEMBL_ID
DB00519 DRUGBANK_ID
C052035 MESH_SUPPLEMENTAL_RECORD_UI
5484727 PUBCHEM_CID
6453 IUPHAR_LIGAND_ID
5746 INN_ID
1T0N3G9CRC UNII
DB14209 DRUGBANK_ID
1546379 RXNORM
107488 MMSL
5448 MMSL
5606 MMSL
5642 MMSL
d04008 MMSL
004452 NDDF
108562001 SNOMEDCT_US
386871006 SNOMEDCT_US
C0165477 UMLSCUI
CHEMBL1201387 ChEMBL_ID
87679-71-8 SECONDARY_CAS_RN
5464097 PUBCHEM_CID
6455 IUPHAR_LIGAND_ID
6370 INN_ID
C061095 MESH_SUPPLEMENTAL_RECORD_UI
RR6866VL0O UNII
CHEBI:141521 CHEBI
1T0N3G9CRC INXIGHT DRUGS
RR6866VL0O INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-052 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-053 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-054 TABLET 4 mg ORAL ANDA 18 sections
Trandolapril Human Prescription Drug Label 1 50090-4120 TABLET 2 mg ORAL ANDA 21 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 50090-4128 TABLET 1 mg ORAL ANDA 19 sections
Mavik HUMAN PRESCRIPTION DRUG LABEL 1 54868-5099 TABLET 4 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5311 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5320 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5548 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL NDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 54868-6061 TABLET 4 mg ORAL ANDA 14 sections
Trandolapril Human Prescription Drug Label 1 57237-089 TABLET 1 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 57237-090 TABLET 2 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 57237-091 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 63629-8003 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril Human Prescription Drug Label 1 65862-164 TABLET 1 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-165 TABLET 2 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-166 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68151-0757 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-566 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-566 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-567 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-567 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-568 TABLET 4 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-568 TABLET 4 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68258-6100 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-294 TABLET, FILM COATED, EXTENDED RELEASE 1 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-295 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-296 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-329 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 71335-1431 TABLET 2 mg ORAL ANDA 20 sections